Active substanceMemantineMemantine Similar drugsTo uncover Acathinol Memantine pills inwards MERCZ PHARMA, LLC Russia Acathinol Memantine pills inwards Merz Pharma GmbH & Co. KG. KGaA Germany Alzheim pills inwards Laboratorios Bago S.A. Argentina Auranex solution inwards Pharmaceutical factory "POLFARMA" JSC Poland Maruksa® pills inwards KRKA-RUS, LLC Russia Maruksa® pills inwards KRKA-RUS, LLC Russia Memaneirin drops inwards BIS, CJSC Russia Memantal® pills inwards FarmSirma Soteks, ZAO Russia Memantine pills inwards FARMZASCHITA NPC, FSUE Russia Memantine pills inwards VERTEKS, AO Russia Memantine pills inwards FARMZASCHITA NPC, GP Russia Memantine pills inwards Pharmaceutical Projects, LLC Russia Memantine pills inwards ATOLL, LLC Russia Memantine Canon pills inwards CANONFARMA PRODUCTION, CJSC Russia Memantine Canon pills inwards CANONFARMA PRODUCTION, CJSC Russia Memantine Canon pills inwards CANONFARMA PRODUCTION, CJSC Russia Memantine Sandoz® pills inwards Sandoz d. Slovenia Memantine Sandoz® pills inwards Sandoz d. Slovenia Memantine-Alvogen pills inwards Alvogen IPKo S.A.L. Luxembourg Memantine Richter pills inwards GEDEON RICHTER, OJSC Hungary Memantine-TL pills inwards TECHNOLOGY OF DRUGS, LTD. Russia Memantinol® pills inwards Farm-Holding, CJSC Russia Mémique pills inwards GlaxoSmithKline Trading, ZAO Russia Memorel® pills inwards NIZHFARM, JSC Russia Noogeron pills inwards Pliva of Hrvatska doo Croatia Noogeron-Teva pills inwards Teva Pharmaceutical Enterprises Co., Ltd. Israel Tingrex® pills inwards GRINDEX, JSC Latvia Dosage form: & nbspFilm coated tablets. ATX: & nbspN.06.D.X.01 MemantineN.06.D.X Other drugs for the treatment of dementia Indications:Dementia of the Alzheimer's type of moderate and severe degree. Overdose:Symptoms: Relatively large overdoses (200 mg and 105 mg / day for 3 days) are expressed by symptoms of fatigue, weakness and / or diarrhea or the absence of symptoms. Overdose up to 140 mg / day. or an unknown amount of the drug is expressed by symptoms associated with the central nervous system (confusion, drowsiness, dizziness, vertigo, anxiety, agitation, hallucinations and gait disturbance) and / or gastrointestinal disturbances (vomiting and diarrhea).In the most serious cases of overdose, the patient survived after taking more than 2000 mg memantine with adverse effects from the nervous system (coma for 10 days, later - diplopia, agitation).The patient received symptomatic therapy and plasmapheresis and recovered without any consequences.Another described case of a serious overdose is 400 mg once. The patient recovered without consequences. There was a reaction from the nervous system: anxiety, psychosis, visual hallucinations, stupor, seizures, drowsiness, unconsciousness.Treatment: symptomatic therapy, gastric lavage, reception of activated charcoal, urine acidification, forced diuresis (if necessary). There is no specific antidote. Interaction:- With simultaneous use with drugs levodopa, dopamine receptor agonists, anticholinergic drugs, the effects of the latter can be intensified. With simultaneous use with barbiturates, neuroleptics, the effect of the latter may decrease. When combined, the effect of dantrolene or baclofen can be altered (enhanced or decreased), so the doses of the drugs should be selected individually.- The simultaneous use of memantine with amantadine should be avoided because of the risk of pharmacotoxic psychosis. Both compounds are NMDA antagonists.Perhaps this applies to ketamine and dextrustorphan.Also, one case of a possible risk of developing pharmacodynamic psychosis with simultaneous use of memantine and phenytoin was documented.- Cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine can also interact with memantine, which leads to a potential risk of an increase in the plasma content of the drug.- There is the possibility of reducing the level of hydrochlorothiazide (HCT) in the serum with the joint use of memantine with HCT.- After the release of memantine on the market in single cases, an increase in the international normalized ratio (INR) in patients receiving concurrent treatment with warfarin was described.However, no causal relationship was established. It is advisable to monitor prothrombin time or INR in patients receiving simultaneous treatment with oral anticoagulants.- Memantine does not inhibit the isoenzymes CYP1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin containing monooxygenases, epoxide hydrolases and in vitro sulfation reactions. With glibenclamide, metformin and donepezil, no interaction effects were recorded.The effect of memantine on the pharmacokinetics of galantamine has not been revealed. Form release / dosage:Tablets, film-coated, 10 mg. Packaging:10 tablets per blister PVC / Al. For 3, 9 blisters together with instructions for medical use in the pack. Storage conditions:At a temperature not higher 25 ° C. Shelf life:3 years.Do not use after the expiry date printed on the package. Terms of leave from pharmacies:On prescription Registration number:LP-002088 Date of registration:04.06.2013 Expiration Date:04.06.2018 The owner of the registration certificate:Pharmaceutical Projects, LLCPharmaceutical Projects, LLC Russia Manufacturer: & nbspHELBA PHARMACEUTICALS, Inc., Co. India Information update date: & nbsp2016-12-06 Illustrated instructions × Illustrated instructions Instructions